Atralin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Atralin

What is Atralin? Definition and Classification

Property Description
Active ingredient Tretinoin
Form Topical Gel (Aqueous base)
Pharmacological class Retinoid, Topical Antiacne Agent
General purpose Normalizes skin cell turnover
Origin Synthetic Vitamin A derivative

Atralin is a specific prescription-only medication formulated as a topical gel. Its sole active pharmaceutical ingredient is Tretinoin, which classifies the medicine as a Retinoid, a synthetic compound derived from Vitamin A.

This classification confirms the drug's role in influencing cellular processes, a function that is clinically recognized. The specific formulation of Tretinoin in Atralin is distinct from other retinoid products due to its focus on providing controlled absorption in a gel base, which is an important consideration for patients seeking effective topical therapy.

Tretinoin Gel: Composition and Delivery System

The Atralin product utilizes an aqueous gel base—a high-water content vehicle—for the effective delivery of the active ingredient, Tretinoin, via topical application.

This unique composition of an aqueous gel vehicle, rather than a heavy cream, sets the Atralin formulation apart. The design of this delivery system optimizes the controlled release and penetration of the Tretinoin compound while minimizing oil content, making it a suitable choice for skin where excessive oiliness or pore blockage is a primary characteristic.

Primary Purpose of Atralin (Tretinoin)

The fundamental purpose of this Tretinoin medicine is to manage and improve skin texture by normalizing the skin's cellular behavior. The Retinoid compound binds to specific cellular receptors, altering the way skin cells grow and differentiate.

This regulatory physiological action ensures that the skin's cell turnover cycle is properly maintained. The overall general benefit is the sustained ability to keep the skin's pores clear and functioning optimally, preventing the abnormal accumulation of cells that leads to pore blockage.

Regulatory References

  1. DailyMed Drug Label (NIH/FDA)

What side effects are possible with Atralin?

Possible Side Effects and Safety Information

The safety profile of Atralin (tretinoin gel) is primarily characterized by dermatological adverse reactions that occur at the application site. Data from regulatory sources show that these skin reactions are generally transient, most often appearing and reaching their peak incidence during the first few weeks of therapy.

Adverse Reactions and Frequency

Adverse reactions are classified by how often they occurred in clinical trials, according to official regulatory labeling:

Frequency Category Adverse Reaction Example Incidence (Atralin Gel)
Very Common Dry skin, Peeling/Scaling/Flaking Skin 10% or more
Common Skin Burning Sensation, Erythema (Redness), Pruritus (Itching), Sunburn 1% to less than 10%

Postmarketing surveillance has also noted cases of temporary hyperpigmentation (skin darkening) and hypopigmentation (skin lightening), although the frequency of these events is not established.


Safety Constraints and Special Populations

Several safety restrictions are documented in the official labeling. The medication is contraindicated for individuals with a known hypersensitivity or allergy to tretinoin or any component in the formulation.

Exposure to sunlight or UV light (photosensitivity) must be minimized during treatment due to increased risk of sunburn. Additionally, Atralin should not be used on sunburned or eczematous skin.

Safety and effectiveness have not been established for use in children under 12 years old or in the geriatric population (65 years and older). Atralin is classified as Pregnancy Category C by the FDA, and caution is required for patients with known fish allergies as the gel contains soluble fish proteins.

Overdose and Emergency Response

The official regulatory profile for Tretinoin topical gel overdose focuses on two distinct exposure types: local and systemic. Information is based strictly on government-authorized prescribing documents.

Local Overdose Manifestations

Overdose resulting from excessive topical application of Atralin will not provide increased efficacy and is documented to cause local skin manifestations. These signs of local irritation include:

  • Marked redness (erythema)
  • Peeling (exfoliation)
  • Local discomfort

Such excessive application generally warrants temporary cessation or reduction of use.

Systemic Overdose and Required Emergency Action

The risk of systemic overdose is strictly confined to cases of accidental oral ingestion of the gel. The regulatory profile states that the resulting effects are similar to those associated with excessive oral intake of Vitamin A (Hypervitaminosis A syndrome).

Immediate medical help is required when individuals exhibit severe, life-threatening systemic signs associated with oral ingestion, including:

  • Collapse
  • Seizure
  • Trouble breathing
  • Inability to be awakened

The official guidance mandates contacting emergency services or a Poison Help line immediately upon recognizing these acute manifestations. Treatment for such systemic overdose is generally described as being symptomatic and supportive. The regulatory information does not list a specific antidote.

Therapeutic Uses of Atralin

What Atralin Treats: Main Uses and Benefits

The Tretinoin formulation in Atralin is primarily a topical treatment used in the field of dermatology for managing Acne Vulgaris in adolescents and adults. The therapy is relevant across conditions characterized by periods of heightened symptoms related to skin blemishes and pore blockages. It is officially indicated for the topical treatment of acne vulgaris.


Atralin may assist with managing a range of acne symptoms, including non-inflammatory lesions like comedones (blackheads and whiteheads), as well as inflammatory lesions such as papules and pustules. By supporting the management of these visible symptoms, the medication assists with maintaining functional stability and supports the patient during difficult episodes by easing distress.

The core benefit lies in controlling the issue of follicular congestion and abnormal skin cell turnover. This helps address symptom clusters that may become intense, making it a common choice for long-term symptom stabilization and maintenance against recurring breakouts.

“Atralin is applied when skin symptoms stem from a continuous physiological disturbance, helping to normalize the cell shedding process.”

This application contributes to improved comfort during periods of heightened symptoms and helps patients cope more steadily with symptom fluctuations.


Quick Fact: Relief for Persistent Acne Symptoms Atralin is considered relevant for easing symptoms that interfere with daily functioning when the condition is persistent or recurrent. It is often used in settings where symptoms require supportive relief.

Regulatory References

  1. NIH DailyMed for Tretinoin gel

Eligibility and Restrictions for Use

Who Can and Cannot Use Atralin? (Official Eligibility Information)

Eligibility for Atralin (tretinoin gel) is determined by specific patient characteristics and physiological states, as outlined in regulatory documentation.

Age and Reproductive Status

  • Age-Based Eligibility: Atralin is indicated for patients 10 years of age and older. Its safety and effectiveness have not been established in children younger than 10 years.
  • Pregnancy and Lactation: The medication is classified as Pregnancy Category C, meaning it should be used only if the potential benefit justifies the potential risk to the fetus. It is not known if the drug passes into human milk, so caution should be exercised when administered to a nursing woman.

Restrictions and Special Cautions

Population/Condition Regulatory Caution Implication
Eczematous Skin Use with utmost caution Potential for severe local irritation.
Sunburned Skin Do not use until fully recovered Heightened susceptibility to sunlight.
Fish Allergy Use with caution The gel contains soluble fish proteins.

No absolute contraindications are formally listed in the dedicated section of the FDA labeling. However, use is prohibited in cases of sunburn and requires careful consideration in populations like pregnant or nursing individuals and those with specific pre-existing skin conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction scope

Category Official Regulatory Statement
Medicinal product categories with documented interactions Topical over-the-counter acne preparations; Concomitant topical medications; Photosensitizing agents (including certain systemic drugs) [Source: FDA].
Specific interacting medicines (if explicitly listed) Benzoyl peroxide; Sulfur; Resorcinol; Salicylic acid [Source: FDA Prescribing Information, Section 7].
Mechanistic basis of interactions (only if stated in label) Pharmacodynamic interaction (cumulative local irritation and drying effects); Pharmacodynamic interaction (augmentation of photosensitivity) [Source: FDA].
Timing-based interaction rules (if applicable) The effects of topical over-the-counter acne preparations must be allowed to subside before use of Atralin Gel is initiated [Source: FDA Prescribing Information, Section 7].
Population-specific interaction notes (if applicable) None explicitly stated in official labeling regarding heightened systemic interaction risk.
Interaction-related restrictions Caution is required with products having a strong drying effect, or high concentrations of alcohol, astringents, spices, or lime [Source: FDA Prescribing Information, Section 7].

Interaction classifications (high-level)

Category Official Regulatory Statement
Interaction severity classification (as defined in official documents) Use with Caution / Timing Required (for local irritants); Risk of Augmented Effect (for photosensitizers) [Source: FDA].
Regulatory basis (EMA / FDA / etc.) United States Food and Drug Administration (FDA) Prescribing Information.
Interaction-context constraints (as defined in official documents) Interactions are constrained to the topical application site and the impact of UV light exposure (photosensitivity).

Resulting interaction structure

The official regulatory documents define the product's interaction structure primarily through pharmacodynamic reinforcement concerning local skin effects and photosensitivity, with no systemic pharmacokinetic interactions documented. The interaction profile is characterized by explicit timing and substance co-administration restrictions intended to mitigate the risk of cumulative local irritation from other topical agents or products containing specific irritating ingredients.

Mechanism of Action

How Atralin Works: Mechanism of Action

Atralin's mechanism is initiated by its active component, tretinoin, acting as an agonist for Nuclear Retinoic Acid Receptors ( RARalpha, RARbeta, RARgamma) . This molecular binding event leads to the direct modulation of gene transcription within skin cells, altering the expression of proteins governing growth, differentiation, and inflammation. This modification of the gene expression profile serves as the core driver for the subsequent cellular and tissue effects.

The mechanism focuses on the regulation of keratinocyte differentiation, normalizing the process of follicular keratinization and increasing the rate of epidermal cell turnover. This physiological change prevents the buildup of cohesive dead cells, contributing to the normalization of follicular patency.

Simultaneously, the drug acts in the dermis by stimulating fibroblasts to increase the synthesis of collagen and elastin while inhibiting Matrix Metalloproteinases (MMPs). This dual action initiates dermal restructuring, leading to changes in dermal architecture and tissue stability. Furthermore, Atralin effects a local anti-inflammatory suppression by downregulating pro-inflammatory transcription factors, thereby modulating the physiological signaling associated with inflammation.

Dosage and Administration Information

The administration of Atralin (Tretinoin 0.05% gel) is strictly limited to topical application on the skin. The medication is not approved for ophthalmic, oral, or intravaginal use. The usage protocol involves a long-term, standardized application routine, requiring the gel to be applied to the entire affected area where lesions occur, rather than only to individual blemishes.

The regimen specifies that a thin layer of the 0.05% gel should be applied once daily in the evening, typically before bedtime. Increasing the amount of gel applied beyond a thin layer does not enhance efficacy and may lead to over-application.

Administration Principle Official Usage Protocol
Preparation Must be applied to skin that has been cleansed thoroughly and allowed to pat dry before application.
Dosing Frequency Once daily, applied in the evening.
Application Constraint Must be kept away from the eyes, mouth, and mucous membranes.
Course Duration Initial therapeutic results typically require two to three weeks of use, with sustained benefit potentially requiring seven or more weeks.

For pediatric use, safety and effectiveness are not established for patients younger than 12 years of age. If an application is missed, the protocol is to skip the missed dose and resume the regular schedule without attempting to apply a double amount. This structured protocol defines the consistent application pattern required for treatment.

Recent Clinical Evidence

Research Evidence: Overview of Clinical Studies

This section provides a summary of the clinical research foundation for Atralin, focusing on the types of studies that support its official indication and the outcomes that were measured in those trials. Research provides context but not individual predictions.


Core Evidence for Topical Acne Vulgaris

The research base for Atralin (tretinoin gel 0.05%) centers on studies of Acne Vulgaris. The core evidence was derived from randomized, double-blind clinical trials. This study type compares the active gel against a vehicle (a matching gel containing no active ingredient, or placebo). This method allows for the examination of symptom patterns within the observed populations.

Researchers primarily measured two categories of outcomes in these trials. First, they monitored changes in lesion counts, specifically documenting the change from the start of the study in both non-inflammatory lesions (like whiteheads and blackheads) and inflammatory lesions (like papules and pustules). Second, they used a Global Severity Score to evaluate the overall change in the skin’s appearance, noting the proportion of participants who reached a specified threshold in severity reduction. This research highlights changes measured during the study period.

Studies monitored outcomes related to both lesion counts and overall skin assessment scores when comparing the active gel to the vehicle gel. Trial reports described the observations related to both lesion counts and the overall skin assessment scores. The evidence contributes to understanding symptom patterns in conditions characterized by fluctuating or episodic manifestations.


Study Duration and Long-Term Follow-up Data

Observations recorded in the core clinical trials for Atralin focused on a short-term follow-up duration, typically concluding at 12 weeks. This length of time was relevant in trials assessing short-term or episodic symptom patterns.

While the 12-week period was sufficient for the primary regulatory review, there is limited information for long-term outcomes specifically for this gel formulation. Studies have been conducted on the active ingredient (Tretinoin) for longer durations, providing additional context. Therefore, long-term effects are not fully established, and long-term outcomes are not well characterized by the product-specific research.


Evidence in Specific Age Groups

The clinical research for Atralin has included a wide range of participants. Specifically, studies explored its use in adolescents and adults with acne, including subjects aged 10 years and older. This means the research provides insight into short-term changes for both younger and older individuals presenting with the condition.

However, data for certain groups remain insufficient. Specifically, clinical data available to regulators did not include subjects over the age of 65 years. Consequently, results apply only to the populations studied, and the evidence for use in the geriatric population is limited.


Research Gaps and Areas of Uncertainty

Research has explored the effects of Atralin under specific conditions, but certain knowledge gaps remain. One key limitation is the follow-up durations were limited; the core evidence is based almost entirely on the short-term 12-week trials. This leaves limited information regarding sustained outcomes and the overall pattern after many months or years of observation.

Furthermore, data for certain groups remain insufficient, particularly for people over 65, meaning research does not determine whether an individual in that age group will respond similarly. Given the use of well-controlled randomized trials, the study methodology for the short-term duration is standard for regulatory evidence; however, the overall picture shows that comparative evidence is lacking for certain populations and that long-term effects are not fully established. Studies help show what has been observed so far, but also highlight what is still uncertain.

Key Studies & References

  1. Tretinoin Gel 0.05% DailyMed Label Information (Pivotal Study Summary)

Frequently Asked Questions (FAQ)

Common questions about Atralin (FAQ)

Q: How is Atralin different from other topical tretinoin brands like Retin-A?

Atralin is defined by its specific aqueous gel base, which sets it apart from other topical tretinoin products. This formulation difference is an important part of the product’s design, as other brands may use creams or other types of vehicles.

Q: Is the active ingredient in Atralin the same as the ingredient in over-the-counter Retinol?

Atralin contains the active ingredient tretinoin, which is a prescription-only retinoid, defined as a synthetic Vitamin A derivative. Regulatory documents do not address or classify over-the-counter retinol.

Q: Does the skin irritation from Atralin usually improve after the first few weeks?

Official information indicates that dermatological adverse reactions, such as irritation and redness, are generally transient. They most often reach their highest frequency during the first few weeks of therapy, which suggests that they may improve or lessen after this initial period.

Q: Can using Atralin make the skin more sensitive to sun exposure?

Yes, official safety information states that exposure to sunlight or ultraviolet (UV) light must be minimized while undergoing treatment. This is due to the potential for photosensitivity and an increased risk of sunburn.

Q: What should I do if the irritation from Atralin becomes severe?

Official patient information describes several management options used to address severe irritation. These may include the temporary reduction of the amount or frequency of application, or temporary or complete discontinuation of use, as determined by a healthcare professional.

Q: What are the possible signs of an allergic reaction to Atralin?

Atralin is contraindicated for individuals with a known hypersensitivity to any component of the formulation. Official documents indicate that signs such as pruritus (itching) or urticaria (hives) should be reported to a healthcare provider.

Q: Can people who have previously used Accutane (isotretinoin) use Atralin for maintenance?

The official indication for Atralin is the topical treatment of acne vulgaris. The regulatory labeling does not contain specific instructions or recommendations regarding its use as a maintenance therapy following treatment with oral isotretinoin (Accutane).

Q: Is it common for people to switch from a cream tretinoin to a gel like Atralin for better tolerance?

Atralin utilizes an aqueous gel base designed to minimize oil content, which is a characteristic that may be suitable for certain skin types. However, regulatory documents do not provide guidance or comparative evidence on the practice of switching between different formulations of tretinoin based on patient tolerance.

Q: Does Atralin help with fading post-acne marks and discoloration?

The mechanism of action for the active ingredient involves stimulating the production of collagen and elastin in the dermis, which is related to overall skin structure. While official documents note the treatment of acne, they do not list the fading of post-acne marks or discoloration as an indicated use for the product.

Q: Is it normal for acne to appear worse during the first few weeks of using Atralin?

Official patient information notes that an apparent worsening, or exacerbation, of inflammatory lesions may occur during the early weeks of treatment. This is part of the treatment process as the skin adjusts.

Q: What is the 'purging' effect people talk about with Atralin?

The 'purging' effect is a common term used by users to describe the initial worsening of inflammatory acne vulgaris. Official documents describe this as an apparent exacerbation that may occur during the first few weeks of therapy.

Q: Can I use Vitamin C serum on the same day as Atralin?

The official regulatory label for Atralin does not list Vitamin C (ascorbic acid) as a substance with a known drug-drug or topical-drug interaction. Interaction warnings are primarily focused on other topical acne preparations that cause local irritation.

Q: Is it okay to use a moisturizer with Atralin?

Official warnings note that mild to moderate skin dryness may be experienced while using Atralin. If this occurs, the use of an appropriate non-irritating moisturizer during the day is an available option for managing dryness.

Q: Can Atralin interact with other oral medications?

According to the official prescribing information, the interaction structure is primarily constrained to the topical application site. Regulatory documents note that no systemic pharmacokinetic interactions are documented for the Atralin gel formulation.

Q: What is the research on using Atralin while breastfeeding?

Official lactation information states that it is not known whether the drug passes into human milk. Caution should be exercised when the medication is administered to a nursing woman.

Q: What happens if Atralin is accidentally applied to sunburned or broken skin?

Atralin is not to be used on sunburned or eczematous (inflamed) skin due to the potential for severe irritation. If the skin is sunburned, regulatory documents require that the skin must fully recover before the product is used again.

Q: Is it true that Atralin can make the skin more sensitive to cold and wind?

Official warnings indicate that weather extremes, such as wind or cold, may also be irritating to skin that is under treatment with tretinoin. This effect should be managed by minimizing exposure.

Q: What does the term 'retinization' mean in the context of using Atralin?

Retinization is a term commonly used to describe the initial adjustment period of the skin to the medication. Regulatory documents refer to this as the initial local skin irritation, including redness and peeling, which occurs during the first few weeks of therapy.

Q: What level of alcohol in topical products might interact poorly with Atralin?

Official prescribing information advises caution with products containing a high concentration of alcohol, as well as astringents, spices, or lime. This is due to the potential for increased local irritation and drying effects when used simultaneously with Atralin.

Q: Can harsh soaps or astringents interfere with how Atralin works?

Caution should be exercised with the use of medicated or abrasive soaps and cleansers, as well as astringents. The primary concern listed in regulatory documents is the risk of cumulative local irritation and drying effects, not interference with the drug’s intended physiological mechanism.

Q: Is Atralin considered appropriate for adult acne?

Atralin is indicated for the topical treatment of acne vulgaris. Clinical studies reviewed by regulators included adolescents and adults with acne, encompassing subjects up to 65 years of age.

Q: Is Atralin used for purposes other than acne, like reducing the appearance of fine lines?

The official regulatory indication for Atralin (tretinoin gel 0.05%) is exclusively the topical treatment of acne vulgaris. No other uses are indicated in the official prescribing information.

Q: Does Atralin stop working if exposed to sunlight?

Regulatory documents state that unprotected exposure to sunlight should be minimized due to the increased risk of photosensitivity and sunburn. The label does not specifically address whether sunlight exposure reduces the medication’s efficacy.

Q: Is it possible for Atralin to cause redness and stinging immediately after applying Atralin?

Redness (erythema) and a skin burning sensation are noted in official documents as common adverse reactions. These effects may be experienced at the application site, particularly during the initial phase of treatment.

Q: Does the gel formulation of Atralin make it better for oily skin?

Atralin utilizes an aqueous gel base, which is designed to minimize oil content. This composition is an important consideration for patients whose skin is primarily characterized by oiliness.

How should Atralin be stored and disposed of?

Atralin (tretinoin) Gel, 0.05% must be stored and handled according to specific regulatory requirements to maintain its stability and prevent risks associated with its formulation.

Required Storage and Handling

The gel must be stored at Controlled Room Temperature, specifically between 20 C to 25 C (68 F to 77 F). It is mandatory to keep away from heat and flame and to avoid freezing the product. The container must be kept tightly closed when not in use.

Child Safety and Disposal

Atralin must be kept out of the reach of children at all times. Disposal of any unused or expired medication should follow local requirements, typically involving designated prescription drug take-back programs. Medicines should not be disposed of by flushing down a toilet or pouring into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Atralin found in:

A-Z Index: